LC3B自噬标记物在复发性前列腺癌中的意义

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
E. S. Voronina, A. Bucharskaya, T. V. Palatova, R. N. Fomkin, N. Navolokin, G. Maslyakova
{"title":"LC3B自噬标记物在复发性前列腺癌中的意义","authors":"E. S. Voronina, A. Bucharskaya, T. V. Palatova, R. N. Fomkin, N. Navolokin, G. Maslyakova","doi":"10.15275/rusomj.2022.0115","DOIUrl":null,"url":null,"abstract":"Objective — To compare the expression of the LC3B autophagy marker before and after treatment with high-intensity focused ultrasound therapy (HIFU) and combined therapies: androgenic deprivation AD + HIFU, AD + radiation therapy in patients with and without recurrent prostate adenocarcinoma. Material and Methods — The objects of our study were biopsy specimens of prostates obtained from 70 patients with prostate adenocarcinoma before and after treatment. The first group consisted of patients without signs of relapse after treatment, as evidenced by a normal blood PSA level, the results of ultrasound procedure and biopsy. The second group included patients who had a recurrence of adenocarcinoma after treatment. Patients received the following cancer treatments: ultrasound ablation (HIFU), combination therapy: androgenic deprivation AD + HIFU, AD + radiation therapy. An immunohistochemical staining in two groups was performed with an anti-LC3B antibody. Results — In the group of patients without relapse, the expression of the autophagy marker sharply decreased in the tumor tissue after treatment, but it increased in the stroma of muscle connective tissue and the vascular wall. In the group of patients with relapse, the expression of anti-LC3B antibody significantly increased in tumor cells, in stroma of muscle connective tissue, and in vascular wall after treatment. In both groups, the magnitude of the autophagy marker expression did not depend on the treatment method. Conclusion — The autophagy is one of the factors contributing to the survival of prostate adenocarcinoma cells after treatment; the increase in autophagic protein expression after treatment in patients with prostate adenocarcinoma can be used to assess the risk of relapse.","PeriodicalId":21426,"journal":{"name":"Russian Open Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2022-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Significance Of LC3B Autophagy Marker In Recurrent Prostate Adenocarcinoma\",\"authors\":\"E. S. Voronina, A. Bucharskaya, T. V. Palatova, R. N. Fomkin, N. Navolokin, G. Maslyakova\",\"doi\":\"10.15275/rusomj.2022.0115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective — To compare the expression of the LC3B autophagy marker before and after treatment with high-intensity focused ultrasound therapy (HIFU) and combined therapies: androgenic deprivation AD + HIFU, AD + radiation therapy in patients with and without recurrent prostate adenocarcinoma. Material and Methods — The objects of our study were biopsy specimens of prostates obtained from 70 patients with prostate adenocarcinoma before and after treatment. The first group consisted of patients without signs of relapse after treatment, as evidenced by a normal blood PSA level, the results of ultrasound procedure and biopsy. The second group included patients who had a recurrence of adenocarcinoma after treatment. Patients received the following cancer treatments: ultrasound ablation (HIFU), combination therapy: androgenic deprivation AD + HIFU, AD + radiation therapy. An immunohistochemical staining in two groups was performed with an anti-LC3B antibody. Results — In the group of patients without relapse, the expression of the autophagy marker sharply decreased in the tumor tissue after treatment, but it increased in the stroma of muscle connective tissue and the vascular wall. In the group of patients with relapse, the expression of anti-LC3B antibody significantly increased in tumor cells, in stroma of muscle connective tissue, and in vascular wall after treatment. In both groups, the magnitude of the autophagy marker expression did not depend on the treatment method. Conclusion — The autophagy is one of the factors contributing to the survival of prostate adenocarcinoma cells after treatment; the increase in autophagic protein expression after treatment in patients with prostate adenocarcinoma can be used to assess the risk of relapse.\",\"PeriodicalId\":21426,\"journal\":{\"name\":\"Russian Open Medical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Russian Open Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15275/rusomj.2022.0115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Open Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15275/rusomj.2022.0115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的-比较复发性前列腺癌患者在接受高强度聚焦超声治疗(HIFU)和雄激素剥夺AD + HIFU、AD +放疗联合治疗前后LC3B自噬标志物的表达。材料和方法:我们研究的对象是70例前列腺腺癌患者治疗前后的前列腺活检标本。第一组由治疗后无复发迹象的患者组成,通过正常的血液PSA水平,超声检查和活检结果证明。第二组包括治疗后腺癌复发的患者。患者接受以下癌症治疗:超声消融术(HIFU),联合治疗:雄激素剥夺AD + HIFU, AD +放疗。两组均采用抗lc3b抗体进行免疫组化染色。结果-在无复发组,治疗后肿瘤组织中自噬标志物的表达急剧下降,而在肌肉结缔组织间质和血管壁中表达升高。复发组治疗后肿瘤细胞、肌肉结缔组织间质、血管壁中抗lc3b抗体表达明显升高。在两组中,自噬标志物的表达量不依赖于治疗方法。结论-自噬是前列腺腺癌细胞治疗后存活的因素之一;前列腺癌患者治疗后自噬蛋白表达的升高可用于评估复发风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Significance Of LC3B Autophagy Marker In Recurrent Prostate Adenocarcinoma
Objective — To compare the expression of the LC3B autophagy marker before and after treatment with high-intensity focused ultrasound therapy (HIFU) and combined therapies: androgenic deprivation AD + HIFU, AD + radiation therapy in patients with and without recurrent prostate adenocarcinoma. Material and Methods — The objects of our study were biopsy specimens of prostates obtained from 70 patients with prostate adenocarcinoma before and after treatment. The first group consisted of patients without signs of relapse after treatment, as evidenced by a normal blood PSA level, the results of ultrasound procedure and biopsy. The second group included patients who had a recurrence of adenocarcinoma after treatment. Patients received the following cancer treatments: ultrasound ablation (HIFU), combination therapy: androgenic deprivation AD + HIFU, AD + radiation therapy. An immunohistochemical staining in two groups was performed with an anti-LC3B antibody. Results — In the group of patients without relapse, the expression of the autophagy marker sharply decreased in the tumor tissue after treatment, but it increased in the stroma of muscle connective tissue and the vascular wall. In the group of patients with relapse, the expression of anti-LC3B antibody significantly increased in tumor cells, in stroma of muscle connective tissue, and in vascular wall after treatment. In both groups, the magnitude of the autophagy marker expression did not depend on the treatment method. Conclusion — The autophagy is one of the factors contributing to the survival of prostate adenocarcinoma cells after treatment; the increase in autophagic protein expression after treatment in patients with prostate adenocarcinoma can be used to assess the risk of relapse.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Russian Open Medical Journal
Russian Open Medical Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
0.90
自引率
0.00%
发文量
39
期刊介绍: Russian Open Medical Journal (RusOMJ) (ISSN 2304-3415) is an international peer reviewed open access e-journal. The website is updated quarterly with the RusOMJ’s latest original research, clinical studies, case reports, reviews, news, and comment articles. This Journal devoted to all field of medicine. All the RusOMJ’s articles are published in full on www.romj.org with open access and no limits on word counts. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. The RusOMJ team is based mainly in Saratov (Russia), although we also have editors elsewhere in Russian and in other countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信